495 related articles for article (PubMed ID: 17087947)
1. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
3. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
[TBL] [Abstract][Full Text] [Related]
4. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
Kerr DJ; Dunn JA; Langman MJ; Smith JL; Midgley RS; Stanley A; Stokes JC; Julier P; Iveson C; Duvvuri R; McConkey CC;
N Engl J Med; 2007 Jul; 357(4):360-9. PubMed ID: 17652651
[TBL] [Abstract][Full Text] [Related]
5. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
Lynch PM
Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
[No Abstract] [Full Text] [Related]
6. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of aspirin to prevent colorectal adenomas.
Baron JA; Cole BF; Sandler RS; Haile RW; Ahnen D; Bresalier R; McKeown-Eyssen G; Summers RW; Rothstein R; Burke CA; Snover DC; Church TR; Allen JI; Beach M; Beck GJ; Bond JH; Byers T; Greenberg ER; Mandel JS; Marcon N; Mott LA; Pearson L; Saibil F; van Stolk RU
N Engl J Med; 2003 Mar; 348(10):891-9. PubMed ID: 12621133
[TBL] [Abstract][Full Text] [Related]
9. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups.
van Adelsberg J; Gann P; Ko AT; Damber JE; Logothetis C; Marberger M; Schmitz-Drager BJ; Tubaro A; Harms CJ; Roehrborn C
Curr Med Res Opin; 2007 Sep; 23(9):2063-70. PubMed ID: 17651539
[TBL] [Abstract][Full Text] [Related]
10. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
Daniels SE; Desjardins PJ; Bird SR; Smugar SS; Tershakovec AM
Clin Ther; 2006 Jul; 28(7):1022-34. PubMed ID: 16990080
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
Benamouzig R; Uzzan B; Martin A; Deyra J; Little J; Girard B; Chaussade S;
Gut; 2010 May; 59(5):622-9. PubMed ID: 20427397
[TBL] [Abstract][Full Text] [Related]
12. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group.
Baron JA; Beach M; Mandel JS; van Stolk RU; Haile RW; Sandler RS; Rothstein R; Summers RW; Snover DC; Beck GJ; Bond JH; Greenberg ER
N Engl J Med; 1999 Jan; 340(2):101-7. PubMed ID: 9887161
[TBL] [Abstract][Full Text] [Related]
13. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
Alberts DS; Martínez ME; Hess LM; Einspahr JG; Green SB; Bhattacharyya AK; Guillen J; Krutzsch M; Batta AK; Salen G; Fales L; Koonce K; Parish D; Clouser M; Roe D; Lance P;
J Natl Cancer Inst; 2005 Jun; 97(11):846-53. PubMed ID: 15928305
[TBL] [Abstract][Full Text] [Related]
14. Aspirin and folic acid for the prevention of recurrent colorectal adenomas.
Logan RF; Grainge MJ; Shepherd VC; Armitage NC; Muir KR;
Gastroenterology; 2008 Jan; 134(1):29-38. PubMed ID: 18022173
[TBL] [Abstract][Full Text] [Related]
15. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
17. Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002.
Bottone FG; Barry WT
Curr Med Res Opin; 2009 Jun; 25(6):1535-50. PubMed ID: 19453292
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network.
Alberts DS; Martínez ME; Roe DJ; Guillén-Rodríguez JM; Marshall JR; van Leeuwen JB; Reid ME; Ritenbaugh C; Vargas PA; Bhattacharyya AB; Earnest DL; Sampliner RE
N Engl J Med; 2000 Apr; 342(16):1156-62. PubMed ID: 10770980
[TBL] [Abstract][Full Text] [Related]
19. The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization.
Lanza E; Yu B; Murphy G; Albert PS; Caan B; Marshall JR; Lance P; Paskett ED; Weissfeld J; Slattery M; Burt R; Iber F; Shike M; Kikendall JW; Brewer BK; Schatzkin A;
Cancer Epidemiol Biomarkers Prev; 2007 Sep; 16(9):1745-52. PubMed ID: 17855692
[TBL] [Abstract][Full Text] [Related]
20. TOCOX--a randomised, double-blind, placebo-controlled trial of rofecoxib (a COX-2-specific prostaglandin inhibitor) for the prevention of preterm delivery in women at high risk.
Groom KM; Shennan AH; Jones BA; Seed P; Bennett PR
BJOG; 2005 Jun; 112(6):725-30. PubMed ID: 15924527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
